Insulet’s latest earnings call carried an upbeat tone, with management emphasizing powerful revenue growth, expanding margins, and a fast-advancing product pipeline. While executives acknowledged ...

Insulet (NASDAQ:PODD) reported what executives described as a “strong start” to fiscal 2026, posting double-digit revenue ...

U.S. growth of 28% was supported by strong type 2 momentum, though results were tempered by higher-than-normal Q1 seasonality ...

Q1 2026 earnings call recap: raised revenue growth guidance, Omnipod 5 Libre 3 Plus integration, margins, risks & Q2 headwind—read now.

In 2024, Insulet shared results from its landmark SECURE-T2D pivotal trial, demonstrating improved glycemic outcomes with Omnipod 5 compared with prior insulin injection or pump therapy in adults with ...

Abstract: Giving credit to prospective debtor is determined by the existence of credit scoring. The accuracy of credit scoring to classify the debtor data is very important. The method that can be ...

Insulet has begun recalling specific lots of its Omnipod 5 insulin pumps in the U.S. after discovering a manufacturing defect that could cause them to leak insulin into the wearable device. The ...

A tear in the tubing of the Omnipod 5 pods may prevent users from getting full insulin doses, raising the risk of serious adverse events from uncontrolled high blood sugar. Insulet recalled some lots ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Acton-based company received ...

Insulet is recalling a portion of its Omnipod 5 insulin patch pumps over a problem that could lead to under-delivery of insulin. Devices from specific lots may have a small tear in the internal tubing ...

Insulet is initiating a voluntary medical device correction for certain lots of its Omnipod 5 pods that may not deliver insulin correctly. The medical device company said Thursday that some pods may ...